Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors
November 13 2018 - 7:00AM
Business Wire
Spectrum Pharmaceuticals Inc., (NASDAQ: SPPI) a
biotechnology company with fully integrated commercial and drug
development operations and a primary focus in hematology and
oncology, today announced the appointment of Jeffrey Vacirca, MD,
FACP to its Board of Directors.
Dr. Vacirca is a practicing oncologist and the current president
of the Community Oncology Alliance, an advocacy group focused on
supporting community oncology clinics. Additionally, Dr. Vacirca is
the medical director of the nation’s largest community oncology
group purchasing organization, International Oncology Network and
the CEO and managing partner at North Shore Hematology Oncology
Associates. He also serves as the vice chairman at Odonate
Therapeutics (NASDAQ: ODT), an oncology company focused on treating
metastatic breast cancer. Furthermore, he has joined the Board of
Directors for One Oncology, an oncologist-led company providing
oncologists with innovative tools to help keep cancer
care in the hands of the providers.
“As a prominent leader within community oncology, Dr. Vacirca
has a reputation and clear understanding of how to successfully
develop and commercialize oncology pharmaceuticals,” said Joe
Turgeon, President and Chief Executive Officer of Spectrum
Pharmaceuticals. “His expertise working across multiple
stakeholders including patient advocacy groups, clinical
investigators, group purchasing organizations, and government
agencies is invaluable and precisely what is needed as Spectrum
advances its two late-stage pipeline products, poziotinib and
ROLONTIS.”
“Joining the Spectrum Board provides me the rare opportunity to
fulfill a passion for patient care while working with a company
developing life changing therapies,” said Dr. Vacirca. “Poziotinib
has the potential to change the treatment paradigm for a subset of
cancer patients that have had no adequate treatment options.
Additionally, Spectrum has developed a novel G-CSF, which is the
first new drug in over fifteen years for use in chemotherapy
induced neutropenia.”
With Dr. Vacirca’s appointment, the Spectrum Board increases to
nine directors, each of whom are nominated annually by the
nominating and corporate governance committee.
About the Spectrum’s Late-Stage Pipeline
Spectrum Pharmaceuticals has two promising late-stage therapies
including poziotinib, an investigational therapy targeting the exon
20 insertion mutation. There are currently no FDA approved targeted
therapies for the exon 20 mutation. Poziotinib is currently being
studied in a pivotal, multicenter Phase 2 trial for non-small cell
lung cancer for patients with the exon 20 mutation. Recent data
from an MD Anderson Phase 2 study of poziotinib demonstrated strong
efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20
mutant NSCLC patients. The second late-stage pipeline product,
ROLONTIS® (eflapegrastim), is a novel G-CSF therapy being
investigated for use in chemotherapy induced neutropenia. Spectrum
Pharmaceuticals plans to file a BLA submission with the FDA for
ROLONTIS by the end of 2018.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in hematology and oncology. Spectrum
currently markets six hematology/oncology drugs and has an advanced
stage pipeline that has the potential to transform the company.
Spectrum's strong track record for in-licensing and acquiring
differentiated drugs, and expertise in clinical development have
generated a robust, diversified, and growing pipeline of product
candidates in advanced-stage Phase 2 and Phase 3 studies. More
information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the company's reports filed with the Securities and
Exchange Commission. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® and ROLONTIS® are registered
trademarks of Spectrum Pharmaceuticals, Inc and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181113005325/en/
Spectrum Pharmaceuticals Inc.Shiv Kapoor, 702-835-6300Vice
President, Strategic Planning & Investor
RelationsInvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024